期刊文献+

促红细胞生成素对高龄慢性心力衰竭并贫血患者的治疗作用 被引量:4

下载PDF
导出
摘要 目的探讨促红细胞生成素(EPO)对高龄慢性充血性心力衰竭合并贫血患者的治疗作用。方法 108例诊断为慢性充血性心力衰竭患者中合并贫血58例纳入本研究。入选患者依顺序单双号法分为对照组与治疗组,各29例。对照组常规抗心力衰竭治疗,按常规剂量应用叶酸、铁剂等补充造血原料。治疗组在对照组治疗基础上,加用EPO 6000IU/周、皮下注射,治疗4个月。结果在高龄慢性充血性心力衰竭患者中贫血的发生率高;心力衰竭越重,贫血更为常见。两组治疗前各相关临床指标比较无差异(P>0.05)。对照组治疗前后比较,射血分数增加(P<0.05),但血红蛋白、左室内径、肾小球滤过率均无改善(P<0.05);治疗组治疗后与治疗前比较血红蛋白增加、左室内径下降、射血分数增高及肾小球滤过率提高,差异有统计学意义(P<0.05)。治疗组心脏结构与功能改善明显优于对照组。结论高龄慢性充血性心力衰竭合并贫血患者加用EPO治疗能更好地纠正贫血与改善心功能。
出处 《心脑血管病防治》 2013年第1期28-30,共3页 CARDIO-CEREBROVASCULAR DISEASE PREVENTION AND TREATMENT
  • 相关文献

参考文献9

  • 1Wexler D, Silverberg D, Blum M, et al. Anaemia as a contribulor to mor- bidity mad mortality in congestive heart failure [ J ]. Nephrol Dial Trmas- plant,2005,20(7) : 11 - 5.
  • 2Komajda M.,Anker S.D.,Charlesworth A.,郭俊.新发贫血对慢性心力衰竭发病率和死亡率的影响:来自COMET研究的结果[J].世界核心医学期刊文摘(心脏病学分册),2006(12):26-27. 被引量:14
  • 3Wexsler D, Silverberg D, Sheps D, et al. The importance of correction of anaemia with erylhropoietin and intravenous iron in severe resistant conges- tive heart failure[ J ]. The European Journal of Heart Failure, 2003, (Su- pl) : 225 - 230.
  • 4吴海云,赵玉生,郑军,等.促红细胞生成素联合铁剂治疗老年人慢性心力衰竭合并贫血48例临床评介[J].中华老年病学杂志,2004,23(2):122-123.
  • 5Silverberg DS, Wexler D, Iaina A. The role of anemfia in the progression of congestive heart failure, ls there a place for e~hropoietin and intra- venous iron[J]. J Nephrol,2004,17(6) :749 - 761.
  • 6Arcasoy MO. The non-haematopoietic biological effects of erythropoietin [ J ]. Br J Haematol, 2008,141 ( 1 ) : 14 - 31.
  • 7Gorge J, Goldstein E, Abashidze A, et al. Erythropoietin promotes en- dothelial progenitor cell proliferative and adhesive properties in a PI 3-ki- nase-dependent manner[ J ]. Cardiovase Res, 2005,68 (2) : 299 - 306.
  • 8胡志辉,张勇.促红细胞生长素应用的新途径[J].华南国防医学杂志,2007,21(6):46-48. 被引量:2
  • 9Silverberg DS. Cardio-nephrology: Cardio renal anemia syndrome. Pro- ceedings of an international symposium [ J ]. Clin Nephrol, 2002,58 ( 1 ) : 1 - 96.

二级参考文献21

  • 1[1]Jelkmann W.Molecular biology of erythropoietin[J].Intern Med,2004,43(8):649-659
  • 2[2]Smith KJ,Bleyer AJ,Little WC,et al.The cardiovascular effects of erythropoietin[J].Cardiovasc Res,2003,59(3):538-548
  • 3[3]Jelkmann W.Erythropoietin:structure,control of production,and function[J].Physiol Rev,1992,72(2):449-489
  • 4[4]Ratajczak J,Majka M,Kijowski J,et al.Biological significance of MAPK,AKT and JAK-STAT protein activation by various erythropoietic factors in normal human early erythroid cells[J].Br J Haematol,2001,115(1):195-204
  • 5[5]Um M,Lodish HF.Antiapoptotic effects of erythropoietin in differentiated neuroblastoma SH-SY5Y cells require activation of both the STAT5 and AKT signaling pathways[J].J Biol Chem,2006,281(9):5648-5656
  • 6[6]Sakanaka M,Wen TC,Matsuda S,et al.In vivo evidence that erythropoietin protects neurons from ischemic damage[J].Proc Natl Acad Sci USA,1998,95(8):4635-4640
  • 7[7]Olivetti G,Abbi R,Quaini F,et al.Apoptosis in the failing human heart[J].N Engl J Med,1997,336(16):1131-1141
  • 8[8]Saraste A,Pulkki K,Kallajoki M,et al.Apoptosis in human acute myocardial infarction[J].Circulation,1997,95(2):320-323
  • 9[9]Grimm C,Wenzel A,Groszer M,et al.HIF-1-induced erythropoietin in the hypoxic retina protects against light-induced retinal degeneration[J].Nat Med,2002,8(7):718-724
  • 10[10]Jaquet K,Krause K,Tawakol-Khodai M,et al.Erythropoietin and VEGF exhibit equal angiogenic potential[J].Microvasc Res,2002,64(2):326-333

共引文献14

同被引文献27

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部